HIMS is growing, but the stock price is becoming increasingly incomprehensible. Executives are reducing their holdings, the options market is bearish, yet revenue is surging. This is truly a test of faith. In the end, it all boils down to one word: twisted. Holding onto the stock but too afraid to sell, fearing missing out on a big rally, yet unable to bring myself to open new positions. Pharmaceutical tech stocks are indeed all about internal struggles—just hold on with a zen mindset.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
